Abstract The purpose of this study was to find a safe dosing regimen for landiolol, an ultra-short-acting badrenergic blocking agent, to rapidly control supraventricular tachyarrhythmias (SVTs) in patients with heart failure (HF). Landiolol is reported to have good effects in the treatment of SVTs after cardiac surgery. We evaluated 52 patients with SVT and symptoms of HF (NYHA class III/IV, 10/42; EF 32 ± 12 %) on admission because of ischaemic disease (n = 10), non-ischaemic cardiomyopathy (n = 32), or valvular disease (n = 10). Paroxysmal/ persistent atrial fibrillation and atrial tachycardia were present in 16 (30 %), 23 (45 %), and 13 (25 %) patients, respectively. The patients first underwent conventional therapy with carperitide, dobutamine, or milrinone. Intravenous landiolol was administered at an infusion rate of 1 lg/kg/min and, if no adverse effects developed, the maintenance dose, titrated to HR and blood pressure response, was increased. At an average dose of 10.8 ± 9.4 lg/kg/min, mean HR significantly decreased significantly from 133 ± 27 to 82 ± 15 beats/min (P \ 0.01), whereas systolic blood pressure did not differ from baseline to attainment of an effective dose level (105 ± 21 vs. 101 ± 19 mmHg, P = ns). Within 60 min after initiation of therapy, all patients had achieved a 20 % reduction in HR at the maintenance dose. Transient asymptomatic hypotension requiring cessation of landiolol therapy occurred in three patients. Intravenous administration of landiolol was both effective in rapidly controlling HR for up to 24 h and useful as bridging treatment to additional therapy of oral b blockade, pulmonary vein catheter ablation, or cardiac resynchronisation therapy in patients with HF.
Introduction
Heart failure (HF), a major cause of cardiac death, is a complex clinical syndrome that can result from any structural or functional cardiac disorder [1] . The majority of patients with HF have a reduced left ventricular ejection fraction (LVEF), often resulting from coexisting coronary artery disease. Atrial fibrillation (AF) is a marker of increased mortality in patients with underling cardiac disease [2] . The two disorders frequently coexist. Most evidence suggests that patients with HF and AF have a worse prognosis than do patients with HF but no AF [3, 4] . The largest studies suggest that patients with HF and supraventricular tachyarrhythmias (SVTs) in general, and AF in particular, have increased rates of HF exacerbation, hospitalisation for HF, and death [5, 6] . Current therapeutic options for patients with HF with AF include heart rate control and anticoagulation or medical therapy to restore and maintain sinus rhythm [7] . It is important that prompt and sustained control of heart rate is achieved [8] . Administration of b-blockade is likely to produce a beneficial effect in the setting of sympathetic hyperactivity that usually accompanies episodes of AF with rapid ventricular rate [9] . Landiolol was developed in Japan and has an ultrashort half-life (4 min), higher b1/b2 selectivity ratio, and weaker negative inotropic effect compared with other intravenous b-blockers [10, 11] . Landiolol is an ultra-short-acting b-adrenergic receptor blocker delivered by continuous intravenous infusion for rate control of SVTs in postoperative patients [12, 13] , acute coronary syndrome (ACS) [14] , and acute decompensated heart failure [15] . However, in the setting of SVTs with HF, the haemodynamic response and effect of landiolol remain unclear. The aim of this study was to evaluate acute haemodynamic effects of landiolol in congestive HF (CHF) patients with SVTs.
Materials and methods

Study population
The subjects of this study included 52 patients who developed SVTs with a ventricular response rate of 100 beats/min or higher in congestive HF, based on an LVEF \40 % on admission to Tsukuba University Hospital from October 2007 to June 2011. In addition, tachycardia (HR [100 beats/min) must have continued for C1 h after standard treatment with diuretics, vasodilators, and inotropes such as dobutamine or milrinone. Among 52 patients, all patients received carperitide (0.025-0.05 lg/kg/min), 43 received dobutamine and 3 received milrinone. Patients with a systolic blood pressure level \80 mmHg, suspected hypovolemia, history of bronchial asthma, and life-threatening noncardiac disease or known malignancy were excluded. No other antiarrhythmic agents were added during infusion of landiolol; however, such drugs were not discontinued if patients were receiving them before the start of the study and blood levels had stabilised. Our study complied with the Declaration of Helsinki; the locally appointed ethics committee approved the research protocol and informed consent was obtained from the subjects.
Study protocol
The endpoint of treatment was a 20 % reduction in heart rate. The drug administration period consisted of initial titration followed by maintenance infusion. The initial intravenous administration dose of landiolol was determined to be 1 lg/kg/min for 10 min in all patients. At the end of 10 min, the patient's vital signs were recorded, and if they had not met the study endpoint, an additional 10-min infusion of landiolol was given at a dose level of 1 lg/kg/min. After this infusion, if the patient had achieved a 20 % reduction in heart rate, a maintenance dose of landiolol was titrated. If there was loss of heart rate control during this period, the landiolol dose could be increased up to a maximum of 20 lg/kg/min. The maintenance dose could also be adjusted downward if needed. We examined each patient's background, which included age, sex, the type of tachycardia, and aetiology of HF, and we analysed heart rate, blood pressure, New York Heart Association (NYHA) classification, and the need for additional therapy of oral b blockade, pulmonary vein (PV) catheter ablation, or cardiac resynchronisation therapy (CRT) in each patient during the stable period after administration of landiolol.
Echocardiographic assessment
Echocardiography was performed immediately on admission by a single operator with the Vivid 7 cardiac ultrasound system (GE Healthcare, Horten, Norway). LV enddiastolic diameter (LVDd), LV end-systolic diameter (LVSd), LV wall thickness, and LVEF were measured by the modified Simpson's method from two-and fourchamber views.
Statistical analysis
All data are expressed as the mean ± SD or median and interquartile range for non-normally distributed data. Comparisons of continuous variables were analysed by unpaired t test or Mann-Whitney U test according to the data distribution. Comparisons of categorical variables between groups were performed by chi-square test without correction for multiplicity. All probability values were considered significant when \0.05.
Results
Patient characteristics
Baseline clinical characteristics of the patients are summarised in Table 1 . The patients comprised 43 (83 %) men and 9 (17 %) women with a mean age of 64.8 ± 13.5 years. Aetiologies of CHF were ischaemic heart disease (10 patients, 20 %), non-ischaemic cardiomyopathy (32 patients, 60 %), and valvular heart disease (10 patients, 20 %). Types of SVT included paroxysmal AF (16 patients, 30 %), persistent AF (23 patients, 45 %), and atrial tachycardia (13 patients, 25 %). NYHA classifications were class III in 10 (19 %) patients and class IV in 42 (81 %) patients. Mean LVEF was 32.3 ± 11.9 %: 37 (71 %) patients had an LVEF of \30 %, and 15 (29 %) patients had an LVEF of 30-40 %. Medications on admission are shown in Table 1 . ACE-inhibitors or ARBs were administered in 24 (46 %) patients, b-adrenergic receptor blockers in 35 (67 %) patients, amiodarone in 39 (75 %) patients, calcium channel blockers in 12 (23 %), and diuretics in 43 (83 %).
Effects of landiolol therapy
The administered dose of landiolol is shown in Fig. 1 , with the average dose being 10.8 ± 9.4 lg/kg/min. Three (50 %) of six patients with low-dose landiolol (1-2 lg/kg/ min) received milrinone (0.25-0.5 lg/kg/min), and most patients with high-dose landiolol (C3 lg/kg/min) received a concomitant administration of dobutamine (Fig. 1 ). There were no differences in LVEF among the groups of maintenance dose of landiolol (P = ns). A significant reduction in heart rate was obtained from 133.2 ± 27.3 beats/min at baseline to 82.0 ± 15.3 beats/min after administration of landiolol (P \ 0.01). The average dose of landiolol was 10.9 ± 9.1 lg/kg/min for AF and 10.1 ± 8.3 lg/kg/min for AT (P = 0.63). There was no significant difference in the reduction of HR after infusion of landiolol between AF and AT (AF: 134.9 ± 16.9 ? 85.1 ± 8.8/min, AT: 130.4 ± 15.9 ? 83.5 ± 9.3/min, P = 0.18). In contrast, systolic blood pressure remained unchanged from 105.1 ± 20.6 to 101.1 ± 19.2 mmHg (P = ns) (Fig. 2) . A significant increase in LVEF was obtained from 32.3 ± 11.9 % at baseline to 39.7 ± 6.5 % after administration of landiolol (P \ 0.01) (Fig. 3) . At baseline, NYHA classification was class III in 10 (19 %) patients and class IV in 42 (81 %) patients.
After administration of landiolol, the general condition of 49 of the 52 patients improved. There were only two patients who had sinus recovery from supraventricular tachyarrhythmia after administration of landiolol. However, three patients developed transient hypotension and landiolol administration was ceased, but treatment with phenylephrine was not required. No adverse effects occurred in any patient throughout the study. Additional bblockers were administered orally in 44 patients after discontinuation of landiolol therapy. Infusion of landiolol was replaced by oral b-blocker within 5 days (mean landiolol treatment duration was 3 ± 1 days). The usage of landiolol overlapped with that of the oral b-blocker for 1 day. After recovery from HF, all patients received additional therapy, including PV catheter ablation in 16 patients, oral administration of b-receptor blockers in 20 patients, CRT in 6 patients, and surgical valve replacement in 6 patients. These patients were discharged from hospital with Data were expressed as means ± SD, or numbers and (%)
AF atrial fibrillation, NYHA New York Heart Association, LVEF left ventricular ejection fraction, LVDd left ventricular end-diastolic diameter, BNP B-type natriuretic peptide, eGFR estimated glomerular filtration rate, ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker (Fig. 4) . A representative case of a responder to landiolol administration is shown in Fig. 5 . In this case, with control of the heart rate, the patient's condition improved without incident, and the patient was treated with CRT-D implantation.
Discussion
The major important findings of the present study are that intravenous administration of landiolol was effective in rapidly controlling heart rate for up to 24 h and was useful as a bridging treatment to additional therapy of oral b blockade, PV catheter ablation, or CRT in patients with HF. These unique features of landiolol represent advantages of great potential merit in critical care medicine.
Landiolol hydrochloride was developed and is commercially available in Japan as an agent of ultra-shortacting and high b1-receptor selectivity. Landiolol has much higher cardioselectivity than esmolol (b1/b2 selectivity of landiolol 255 vs. esmolol 33) and is also shorter acting than esmolol (elimination half times: landiolol 4 min vs. esmolol 9 min). The efficacy and safety of landiolol have been shown in specific clinical settings, i.e., in patients Fig. 4 Changes in New York Heart Association (NYHA) functional class on admission, after intravenous administration of landiolol, and after additional therapy, such as oral administration of b-adrenergic receptor blockers, pulmonary vein catheter ablation, cardiac resynchronisation therapy (CRT), or valve replacement surgery. Asterisk indicates that administration of landiolol was stopped in three patients Fig. 5 A 73-year-old man with a past history of idiopathic dilated cardiomyopathy admitted with worsening heart failure and tachycardic atrial fibrillation. His heart rate was 130 bpm and blood pressure was 80/50 mmHg. Echocardiogram showed a LVEF of 13 % with severe LV enlargement and dyssynchrony in LV motion. We began landiolol administration at a dosage of 1 lg/kg/min, with the final maintenance dose at 4 lg/kg/min, and reduced his heart rate to 80 bpm within 40 min after beginning administration. HR, heart rate; sBP, systolic blood pressure; SpO 2 , peripheral blood oxygen saturation Heart Vessels (2014) 29:464-469 467
with AF and SVT after cardiac surgery [12, 13] , and ACS [14] . In the emergency management of hypertension, tachycardia, or arrhythmia in critical care units, emergency rooms, and surgery, landiolol is effective by attenuating haemodynamic responses from sympathetic activation or endogenous catecholamine release. With careful titration and monitoring of the patient, landiolol is relatively safe in the management of SVTs associated with CHF. Different dosage schedules have been used as per the clinical setting and the diagnosis. Generally, landiolol is infused intravenously in doses ranging from 40 lg/kg/min, along with an initial loading dose or bolus. Adverse effects such as hypotension due to b-blockade can be corrected by downtitrating or discontinuing the infusion with complete disappearance of clinical effects within 15 min [16] . Therefore, as an ultra-short-acting b-blocker, landiolol is an important therapeutic option in the acute clinical setting. This favourable property of landiolol allows easy titration and results in fewer side effects than with other long-acting b1-blockers, factors that are considered to be suitable for management of haemodynamic response for SVTs in patients with CHF. Esmolol also has been shown to control heart rate and blood pressure during episodes of acute myocardial ischaemia. Clinical studies indicate that the efficacy of esmolol is equivalent to that of propranolol and verapamil for control of SVT. The most commonly observed adverse effect seen in clinical trials was asymptomatic hypotension. Hypotension may be minimised by titrating to the minimum effective dose and is readily reversed within 30 min of discontinuing the infusion of esmolol [17] . Esmolol is effective in rapidly controlling heart rate for up to 24 h and is well tolerated, but it may produce treatment-limiting hypotension in a small number of patients [18, 19] . Therefore, esmolol has not always been used for control of SVT in the clinical setting with HF. Digoxin has been used for control of AF in patients with HF [20] , but the onset of its clinical effects is slow and unpredictable [21, 22] . Intravenous verapamil is also useful, but its effects are short-lived because it is not traditionally given by continuous infusion. In the present study, we could administer landiolol safely to all 52 patients with LV dysfunction and could manage the heart rate of SVTs with a 2-to 20-lg/kg/ min dose of landiolol. At an average dose of 10.8 ± 9.4 lg/kg/min, mean HR was significantly decreased from 133 ± 27 to 82 ± 15 bpm for SVTs with HF. Maximum dosage of landiolol was widely diverse from low dose to high dose. Kobayashi et al. [15] demonstrated that higher doses of landiolol (3.0 lg/kg/min) suppress cardiac function in patients with severe LV dysfunction. However, whereas 71 % patients had an LVEF of \30 and 81 % patients had severe symptomatic status (NYHA IV) in this study, administration of high-dose landiolol did not suppress cardiac function even in severe LV dysfunction. It was speculated that most patients with high-dose landiolol received concomitant dobutamine therapy. Thus, a vicious circle might be discontinued from LV dysfunction and tachycardia after administration of high-dose landiolol with concomitant inotropic therapy. Continuous intravenous infusion of landiolol decreased the heart rate without influencing the blood pressure, and this dosing regimen for landiolol may be effective in controlling the heart rate in patients with LV dysfunction. There were only two patients who had sinus recovery from supraventricular tachyarrhythmia after administration of landiolol. It was only possible for the agent to control the heart rate. We continued landiolol administration until recovery to a stable condition, when we could provide additional therapy, such as oral administration of b-adrenergic receptor blockers, PV catheter ablation for AF, CRT, or cardiac surgery for valve replacement. After these additional therapies, almost all patients ultimately recovered from HF and were discharged from the hospital.
Clinical limitations
This study has some limitations. First, this study had a nonrandomised observational design, was performed at a single center, and had a small sample size. Second, other haemodynamic parameters such as cardiac output, pulmonary artery pressure, and pulmonary capillary wedge pressure were not assessed because a pulmonary artery catheter was not inserted in any of the study patients. Third, this study was limited to short-term haemodynamic response; therefore, there were no long-term data with respect to prognostic benefit.
Conclusions
Intravenous administration of landiolol was effective in rapidly controlling heart rate for up to 24 h in patients with SVT and HF and was useful as a bridging treatment to additional treatment of oral b blockade, catheter ablation, or CRT.
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